DOI: 10.1055/s-00000129

Kardiologie up2date

References

Koenig W, Ridker PM.
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5 % or Framingham risk > 20 %: post hoc analyses of the JUPITER trial requested by European health authorities. 
Eur Heart J 2010; [Epub ahead of print]: -  

Download Bibliographical Data

Search in: